Fig. 2
From: Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Neuroblastoma cell lines show bimodal responses to treatment with the MEK1/2 inhibitor binimetinib. a-f Neuroblastoma cells were treated with increasing concentrations of binimetinib for 24, 48, 72, 96, or 120 h and cell viability was determined by MTT assays. CHP-212 (log scale) (a), SK-N-BE(2) (b), SK-N-AS (c), and SJ-NB-10 (d) cells are sensitive to binimetinib treatment; e CHP-134, Kelly, LAN-5, NGP, and SK-N-DZ cells maintain resistance to binimetinib treatment after 120 h of drug exposure. f IC50 values (μM) were calculated for cells treated with binimetinib for 120 h. g Densitometry analysis was performed on Western blots from Fig. 1b to quantify relative phospho-ERK (pERK/ERK) protein levels in neuroblastoma tumor cell lines sensitive to binimetinib (“sensitive”) or resistant to binimetinib (“resistant”) h CHP-212 cells were treated with 1 μM binimetinib for 6 h (left two lanes) or 8 h (right two lanes) and SJ-NB-10 cells were treated with 1 μM binimetinib for 96 h (left two lanes) or 120 h (right two lanes). CHP-134 and NGP cells were treated with 1 μM or 10 μM binimetinib for 120 h. Cells were then lysed and Western blots for total and cleaved PARP were performed. Vinculin was used as a loading control